-+ 0.00%
-+ 0.00%
-+ 0.00%

3 ETFs For Pfizer After Its Autoimmune Disease Deal

Simply Wall St·11/18/2026 14:13:42
Listen to the news

Owning Pfizer directly means your results lean heavily on Pfizer specific issues. Simply Wall St highlights risks like regulatory and political actions on drug pricing that could force Pfizer to accept lower prices or higher mandatory discounts on key medicines. An exchange traded fund that holds Pfizer alongside other businesses reduces how much those single company risks can move your portfolio, and also mutes any big upside from Pfizer at the same time.

Pfizer has agreed to license Starna Therapeutics programs that use its in vivo cell technology to target autoimmune disease. The deal gives Pfizer worldwide rights outside Greater China and adds new treatments in inflammation, immunology and cancer to its research pipeline. Investors who want that story inside a wider basket might consider FDL, IHE or FTXH as ways to hold Pfizer through a fund.

Fund Pfizer weight Rank in fund by weight 5-year annualised return after fees Fee Assets
First Trust Morningstar Dividend Leaders Index Fund (FDL) 6.18% #4 of 101 13.9% 0.43% US$8.56 billion
iShares U.S. Pharmaceuticals ETF (IHE) 4.31% #6 of 56 13.0% 0.37% US$1.74 billion
First Trust Nasdaq Pharmaceuticals ETF (FTXH) 6.8% #4 of 51 11.8% 0.6% US$1.20 billion

Prefer to pick the companies yourself? Start with 37 high quality undervalued stocks.

First Trust Morningstar Dividend Leaders Index Fund (FDL)

FDL gives you Pfizer as a solid slice of the portfolio, with about 6.18% of assets, so each US$1,000 holds roughly US$62 in the drug company. The rest of the exchange traded fund is spread across high dividend sectors, with tobacco at 11.2%, integrated telecom services at 9.5%, and other pharmaceuticals at 9.2%. Chevron and Verizon Communications together make up 15.4% of assets, and Philip Morris International is another sizeable holding. As a result, your Pfizer position sits inside a mix that leans toward cash generating US businesses.

Large one off items that hit Pfizer’s financial results can still move FDL, because the stock is a real chunk of the exchange traded fund. Other sectors in the portfolio, such as electric utilities at 9.0% or integrated oil and gas at 8.7%, depend on very different drivers from pharmaceutical earnings. These differences mean those parts can sometimes offset a company specific shock. These sector weights give you income focused diversification around Pfizer, but they cannot remove the uncertainty around future one off charges inside the drug maker.

See how FDL's price compares with analysts' targets for its holdings.

iShares U.S. Pharmaceuticals ETF (IHE)

Pfizer takes a modest role in IHE at 4.31% of the portfolio, so each US$1,000 in the fund holds roughly US$43 in the stock. The exchange traded fund is almost entirely pharmaceuticals at 99.8%, with Eli Lilly at 26.59% and Johnson & Johnson at 22.16% driving a lot of the outcome. You are getting Pfizer wrapped inside a tightly focused group of large drug makers rather than a broad market mix.

Pfizer carries a high level of debt, and that is a company specific financial risk. IHE spreads your money across other drug manufacturers, so balance sheets at Eli Lilly, Johnson & Johnson and the rest of the portfolio can soften the impact if Pfizer’s leverage worries investors. You are still relying on a sector where many businesses face similar pressures around pipelines, regulation and healthcare spending.

Uncover whether IHE has kept pace with the market over the past week, year and five years

First Trust Nasdaq Pharmaceuticals ETF (FTXH)

Eli Lilly and AbbVie together shape a meaningful slice of FTXH, and their drug portfolios pull much of the fund toward large US healthcare groups. Pfizer is the fourth largest holding at 6.8% of assets, so each US$1,000 in FTXH puts about US$68 into Pfizer while the rest spreads across 51 stocks. About 48.0% of the exchange traded fund tracks biotechnology companies, 46.1% is in pharmaceuticals, and 5.2% goes to life sciences tools and services. About 41% of FTXH overlaps with IHE, yet its heavier biotechnology tilt takes it in a different direction.

Pfizer’s dividend of 6.04% is not well covered by earnings, which exposes anyone holding the stock directly to the risk that management eventually resets payouts to match cash flow. FTXH cannot fully blunt that because many pharmaceutical stocks face their own questions about sustaining dividends and research spending, and a biotechnology heavy mix brings other uncertainties tied to clinical results. You still gain something the single Pfizer stock cannot offer, because your money is spread across several healthcare industries and more than fifty individual companies.

See what you'd actually own if you bought FTXH, from its 51 positions to how much sits in the top 10.

Choosing how you want Pfizer exposure

Your real decision here is what you want wrapped around Pfizer while it works on new projects like the Starna autoimmune deal. FDL gives you a chunky Pfizer stake, about US$62 per US$1,000, inside a wide mix of 101 holdings across sectors, for a fee of roughly US$43 a year on US$10,000. IHE charges the lowest fee at about US$37 a year and keeps you in 56 pharmaceutical stocks, closer to a healthcare cluster than a broad market blend. FTXH asks the most on cost at about US$60, tilts toward biotechnology across 51 companies and keeps a similar Pfizer slice to FDL.

One question to settle before choosing is this: Do you want your Pfizer exposure sitting in a multi sector income fund, a concentrated drug group or a biotech heavy pharmaceutical mix, knowing the drug pricing debate can affect all of them in different ways over time?

With 26.59% of IHE riding on Eli Lilly, its next few years matter as much as the fund's. See the earnings forecasts for Eli Lilly.

Fund data as of 13 November 2026. Portfolio holdings as of 13 November 2026.